AMSBIO’s STEM-CELLBANKER animal-free cryopreservation media has played a role in the development of a cell therapy for Parkinson’s Disease that will soon be going into clinical trials.
Parkinson’s disease is one of the most common neurodegenerative diseases worldwide. Therapy largely includes augmentation of dopamine levels in the brain via dopamine supplements or agonists or by inhibiting dopamine degradation. This methodology is symptomatic but not long-lasting, and unfortunately has no neuroprotective effect.
A pioneering study from the Centre for Stem Cell Biology at the Memorial Sloan Kettering Cancer Centre (USA) has focused on developing stem cell-derived midbrain dopamine progenitors for the treatment of Parkinson’s Disease. The study highlighted, amongst other things, that scientists have been able to demonstrate the efficacy of STEM-CELLBANKER to store, thaw and then recover these manufactured cells for clinical use in patients.
STEM-CELLBANKER is a ready-to-use, chemically defined, animal-free freezing medium manufactured under GMP conditions. It is optimised for embryonic stem (ES) and induced pluripotent stem (iPS) cell storage, as well as being a suitable solution for the cryopreservation of other fragile cell types. Containing only European or US Pharmacopoeia graded ingredients, it is also available as a DMSO free formulation. The media significantly increases cell viability while maintaining cell pluripotency, normal karyotype and proliferation ability after freeze-thaw.
To read the Parkinson’s Disease cell therapy paper in full please visit https://bit.ly/3eYwZ5L. For further information including a video introduction to STEM-CELLBANKER please CLICK HERE or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.
